KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer

BACKGROUND/AIMS: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based t...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sehhoon, Kim, Ji-Yeon, Lee, Se-Hoon, Suh, Beomseok, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432792/
https://www.ncbi.nlm.nih.gov/pubmed/28407465
http://dx.doi.org/10.3904/kjim.2015.299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432792/
https://www.ncbi.nlm.nih.gov/pubmed/28407465
http://dx.doi.org/10.3904/kjim.2015.299

Ejemplares similares